https://www.zacks.com/stock/news/2207538/corcept-cort-stock-rises-on-upbeat-revenue-guidance-for-2024?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207538
Jan 09, 2024 - Corcept (CORT) issues encouraging preliminary results for the fourth quarter and full-year 2023. Shares of the company rise on robust 2024 revenue guidance.
zc:-3470341698456354730
0
https://www.zacks.com/stock/news/2209026/c4-cccc-up-6-on-restructuring-plan-to-curb-cash-burn?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2209026
Jan 11, 2024 - The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.
zc:-5547571457753162198
0
https://www.zacks.com/stock/news/2215142/novartis-nvs-to-report-q4-earnings-is-a-beat-in-store?cid=CS-ZC-FT-analyst_blog|earnings_preview-2215142
Jan 24, 2024 - Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.
zc:4097031735617591926
0
https://www.zacks.com/stock/news/2217328/gsk-gears-up-for-q4-earnings-will-it-surpass-estimates?cid=CS-ZC-FT-analyst_blog|earnings_preview-2217328
Jan 29, 2024 - We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.
zc:2736014490641346597
0
https://www.zacks.com/stock/news/2217012/countdown-to-merck-mrk-q4-earnings-wall-street-forecasts-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2217012
Jan 29, 2024 - Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.
zc:-4513296188023377535
0
https://www.zacks.com/stock/news/2219647/merck-mrk-q4-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2219647
Feb 01, 2024 - The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
zc:8433287993432158680
0
https://www.zacks.com/stock/news/2220267/stock-market-news-for-feb-2-2024?cid=CS-ZC-FT-market_news-2220267
Feb 02, 2024 - U.S. stocks closed higher on Thursday as they tried to recover from a massive selloff in the previous session after the Federal Reserve held interest rates steady but also said that a rate cut in March is unlikely.
zc:-4374715891465124759
0
https://www.zacks.com/stock/news/2221915/merck-mrk-unit-to-buy-elanco-s-aqua-business-for-1-3b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221915
Feb 06, 2024 - Merck's (MRK) Animal Health unit is set to strengthen its position with the acquisition of Elanco Animal Health's aqua business for $1.3 billion. The transaction is expected to close by mid-2024.
zc:4074377508497917052
0
https://www.zacks.com/stock/news/2224190/pharma-stock-roundup-azn-lly-s-q4-earnings-nvo-nvs-mrk-s-m-a-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-2224190
Feb 09, 2024 - Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.
zc:4789500609393632382
0
https://www.zacks.com/stock/news/2227548/corcept-cort-q4-earnings-beat-estimates-korlym-sales-grow?cid=CS-ZC-FT-analyst_blog|earnings_article-2227548
Feb 16, 2024 - Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.
zc:-7598314335784966354
0